Dr. Vincent Lam, M.D.
Medical Oncology (Medical Oncology Physician)
201 N Broadway St, Box 8125
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 135
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of California, San Francisco School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MD license D75865
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Johns Hopkins Bayview Medical Center Baltimore, MD
Medical groups
- Johns Hopkins University (2,909 clinicians)
- Agape Physical Therapy and Sports Rehabilitation LP (678 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 135
- Services billed
- 396
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 173 | 85 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 29 |
| Prochlorperazine Maleate Other prescribers in Baltimore, MD | 27 |
| Alecensa (alectinib hcl) | 14 |
| Ondansetron Hcl Other prescribers in Baltimore, MD | 14 |
| Lumakras (sotorasib) | 13 |
| Dexamethasone Other prescribers in Baltimore, MD | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 18 payments worth $8,656 in total to this clinician.
| Eli Lilly and Company | $4,438 |
|---|---|
| Roche Molecular Systems, Inc. | $3,863 |
| AstraZeneca Pharmaceuticals LP | $112 |
| Caris Mpi, Inc. | $105 |
| Genentech, Inc. | $76.27 |
| Pfizer Inc. | $34.46 |
| Daiichi Sankyo Inc. | $28.00 |
| Consulting Fee | $4,400 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Travel and Lodging | $1,453 |
| Education | $850 |
| Food and Beverage | $454 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Feb 26, 2025 | Consulting Fee | $2,800 |
| Eli Lilly and Company Feb 26, 2025 | Consulting Fee | $1,600 |
| Roche Molecular Systems, Inc. Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Education in-kind | $850 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $445 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $375 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $212 |
| Roche Molecular Systems, Inc. Mar 31, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $212 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $62.61 |
| Roche Molecular Systems, Inc. Apr 3, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $57.84 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 25, 2025 | Travel and Lodging LORBRENA · ONCOLOGY · travel to CHICAGO, IL · in-kind | $34.46 |
| Roche Molecular Systems, Inc. Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Roche Molecular Systems, Inc. Jun 11, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $54.00 |
| Roche Molecular Systems, Inc. Apr 3, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $57.84 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Education in-kind | $850 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $445 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $375 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $212 |
| Roche Molecular Systems, Inc. Apr 1, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $62.61 |
| Roche Molecular Systems, Inc. Mar 31, 2025 | Travel and Lodging travel to Tucson, AZ · in-kind | $212 |
| Eli Lilly and Company Feb 26, 2025 | Consulting Fee | $2,800 |
| Eli Lilly and Company Feb 26, 2025 | Consulting Fee | $1,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $428,531 in research payments for these studies, mostly to the institutions running them.
- Neopeptide vaccine to forestall acquired resistance in advanced ALK+ non-small cell lung cancer
Gilead Sciences, Inc. - A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo Inc. · Recruiting · NCT06172478 - An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
Novartis Pharmaceuticals Corporation - A Phase 1b2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan T-DXd Monotherapy …
AstraZeneca Pharmaceuticals LP - BNT116-01
BioNTech SE - A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastati…
Merck Sharp & Dohme LLC - BNT116
BioNTech SE - A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib E7080,MK-7902 plus Pembrolizumab MK-3475 plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participant…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.